The blood test for the detection oflatent infection and TB disease.
HOW THE T-SPOT.TB TEST IS USED
Preventative screening amongst immunocompromisedpatient groups including:HIV, anti-TNFα, cancer chemotherapy, renal dialysis and transplant patients
Targeted testing of high risk populations including:TB suspects, close contacts, immigrants, prisons, care-homes
Pre-employment and regular screening of key professions:Healthcare professionals/occupational health
T-SPOT.TB Test Advantages at a Glance
Single blood sample. No repeat visit
Unaffected by BCG vaccination and common non-tuberculousmycobacteria
Unrivalled sensitivity, maintained even in the immunocompromised
A cost-effective model for TB control
Contact Oxford Immunotec for further information.T-SPOT® and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.© Oxford Immunotec Ltd. 2013 All rights reserved. www.oxfordimmunotec.comOxford Immunotec Limited, 94C Innovation Drive, Milton Park, Abingdon, Oxfordshire OX14 4RZ, UKTel: +44 (0)1235 442780 Fax: +44 (0)1235 442781 Email: [email protected]
LP-TB-UK-V8
Antigens licensed fromStatens Serum Institut
Denmark
Spot the hidden danger
HOW THE T-SPOT®.TB TEST HELPS YOU
The T-SPOT. test gives you accurate results in all patientgroups, time after time with minimum effort
SensitivityThe T-SPOT.TB test has a sensitivity of 95.6%1which is maintained even in theimmunocompromised2, 3 including HIV infected subjects4. Compared to other assays,the T-SPOT.TB test identifies a higher percentage of infected subjects and can be used tohelp rule-out active disease in TB suspects in just 24 hours.
SpecificityThe T-SPOT.TB test uses the RD1 antigens, ESAT-6 and CFP10, which ensure it does not crossreact with the BCG vaccine or most environmental mycobacteria5, 6. Since the specificity ofthe T-SPOT.TB test is 97.1%7, false positives are rare so unnecessary chemoprophylaxisand follow-up is avoided.
SimplicityThe T-SPOT.TB test requires a single blood sample so only one visit is required. Blood can becollected in Vacutainer®, Cell Preparation Tubes or any readily available lithium heparin blood tube.
Cost-effectivenessAs the T-SPOT.TB test dramatically reduces the number of false positive and false negativeresults, it helps ensure that therapy is targeted at people who are truly infected8,9.
HOW THE T-SPOT.TB TEST WORKS
For full technical details visit www.oxfordimmunotec.com
1. T-SPOT.TB Pivotal Clinical Trial (PI-TB-US-V1)2. Meier T. el al. Eur J Clin Microbiol Infect Dis 24: 529–536, 20053. Lee JY. et al. Eur Respir J 2006; 28: 24–304. Clarke S. et al. Clin Exp Immunol 2007 150(2):238-445. Adams L et al. Scandinavian Journal of Infectious Diseases.
2008, 1-8
6. van Leeuwen R et al. Eur Respir J 2007; 29: 605–6077. T-SPOT.TB Pivotal Clinical Trial (PI-TB-US-V1)8. Wrighton-Smith P. et al. Eur Respir J 2006; 28: 45–509. Diel R. et al. ERJ 2007 30: 321-332